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Obesity has reached epidemic proportions in the United States over the past few decades 
and now affects more than one-third of the adult population. In recent years, obesity has been 
linked to increased risk of morbidity and mortality from influenza infection. The influenza 
vaccine is the most effective way to prevent infection with the influenza virus, however, despite 
vaccination, obese individuals have twice the risk of influenza or influenza-like-illness. Obesity 
has been shown to impair T cell activation and function. What is not known is how obesity 
causes the dysfunction. Recent studies have demonstrated that T cell function is heavily reliant 
on cellular metabolism and T cells will switch their metabolic profile in response to extracellular 
stimuli. Inflamed visceral adiposity, caused by inflammatory cells infiltrating hypertrophic 
adipose tissue, is a major hallmark of obesity. Visceral adipocytes of obese individuals release 
high levels of leptin and other pro-inflammatory cytokines into the serum. These changes in the 
extracellular environment of T cells may influence their metabolic profile and in turn, impair 
their function. Therefore, we hypothesized that the metabolic drug metformin would improve T 
cell function. We show that, compared to obese adults, influenza-vaccinated obese adults 
prescribed metformin have improved CD8+ memory T cell responses to in vitro challenge with 
influenza virus. T cells of obese metformin-treated adults express higher levels of activation and 
functional markers. These results suggest that metformin may help to restore memory T cell 
function and act as an immune-enhancing agent for obese individuals at the time of vaccination. 
Further investigation into the metabolic effects of metformin on T cells is needed to uncover the 
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CHAPTER I - BACKGROUND 
Obesity 
In the United States, and globally, rates of obesity have greatly increased. Obesity is 
defined using a measure called the body mass index (BMI), which is a numerical relationship 
between one’s weight (kg) and height (m). BMI is reported in kilograms per meter squared 
(kg/m2). Over one-third of the United States population  is obese (BMI ≥ 30 kg/m2) and over 
two-thirds are overweight or obese (BMI ≥ 25 kg/m2).1 The rise of obesity has become an 
economic strain on our health care system, with $190 billion (21% of total) in healthcare 
expenditures spent every year on obesity and obesity-related conditions.2  The causes of this 
obesity epidemic are numerous and complex, and the consequences are likewise. Genetic, 
physiologic, environmental, psychological, social, and economic factors all contribute to the 
obesity epidemic in varying degrees.  
The most common cause of obesity is the consumption of excess energy relative to 
energy expenditure.3 Over the past few decades, the food environment has changed drastically in 
a way that promotes overeating. Energy dense foods are now both highly available and 
affordable. Whereas, in the past, food insecurity and poverty were associated with thinness and 
being underweight, because of the availability and cheapness of highly processed, calorie dense 
foods, poverty is often now associated with high levels of obesity.3 In combination with over 
consumption of energy dense foods, physical activity has also decreased over the same time 
frame, with fewer than 50% of US adults engaging in the CDC recommended level of physical 




across age, sex, and race, with alarming increases in childhood obesity, predisposing young 
people to numerous other health complications.2 
While obesity is generally defined by excess body weight for height, it is more 
importantly associated with increased abdominal adiposity that can manifest metabolically.2 
Abdominal adiposity is thought to be primarily visceral, as opposed to sub-cutaneous fat, and is 
associated with metabolic dysregulation2. This excess visceral adiposity leads to systemic 
chronic low grade inflammation that originates from the inflamed adipose tissue. In response to 
excess lipid stores, visceral adipocytes release inflammatory mediators, such as interleukin-6 
(IL-6) and TNF-α, that recruit pro-inflammatory immune cells and disrupt systemic metabolism 
through reducing insulin sensitivity.4 Excess fat in visceral adipocytes also signals increased 
release of leptin, leading to hyperleptinima,  concomitantly with reduced release of adiponectin, 
which has also been associated with a decrease in insulin sensitivity.4 
Obesity is associated with many other chronic ailments such as type II diabetes (T2D), 
cardiovascular disease and metabolic syndrome.5 Metabolic syndrome is the culmination of 
metabolically related risk factors for cardiovascular disease (CVD) risk and diabetes. Having 
three of the five following complications results in a diagnosis of metabolic syndrome: 
hyperglycemia, elevated blood pressure, elevated serum triglyceride levels, low high-density 
lipoprotein cholesterol levels, and obesity (particularly central adiposity).6  
Obese individuals have also been found to be more prone to infections.7,8 In a large 
retrospective study involving 22,666 consecutive patients undergoing a coronary artery bypass 
grafting surgery, subjects with a BMI greater than 34 kg/m2 had 1.8 – 3.7 times the risk of 
postoperative infection than those of a lower BMI (26 – 26.9 kg/m2).8 Obesity has also been 




nine-year-old school children, increased BMI was found to be positively associated with acute 
respiratory infection, where overweight children had twice the risk of infection.8 A recent study 
was conducted looking broadly at respiratory tract infections and the role that obesity plays in 
their pathologies.9 They recruited 1455 participants aged 18-70 and invited them to self-report 
incidents of upper and lower respiratory infections over the span of 18 months. Based on the 
diary entries collected and analyzed, obesity was found to be associated with both lower (OR: 
2.02, 95% CI: 1.35-3.00) and upper (OR:1.55, 95% CI: 1.22-1.96) respiratory tract infections. 
Through these and other studies8,10, it has become apparent that obesity contributes to a 
compromised immune system. 
Obesity and immune function  
The immune system functions as a highly complex system with many specialized cells 
and secreted proteins. Crucial to the health of the host is the ability of the immune system to 
correctly recognize and react to harmful, foreign pathogens. For example, in the case of the 
influenza A virus, an airborne pathogen that infects millions of people annually worldwide, an 
efficient immune response could prevent the host from ever experiencing symptoms of the 
infection. The influenza virus is comprised of a spherical protein that envelopes segmented 
single stranded viral RNA. The external area of the virus is studded with one of 16 possible 
hemagglutinin (HA) and 9 possible neuraminidase (NA) glycoprotein spikes, which are used to 
classify the virus and are often the target of influenza vaccines and antibodies.11  
Influenza enters the cell by endocytosis following the binding of its hemagglutinin 
glycoprotein to the sialic acid receptor on the surface of host’s cell. The virus releases its RNA 
into the nucleus of the cell where it is transcribed into mRNA and released into the cytosol to be 




HA and NA proteins produced by the host cell are associated with lipid rafts on the plasma 
membrane of host cell. The HA proteins alter the curvature of the membrane, allowing the viral 
RNA to be packaged inside the envelope proteins. The virus is therefore coated in the host’s 
cellular lipid bilayer and envelope proteins in the lipid raft and buds out of the cell.12  
 When the pathogen first breaches the epithelial cells of the respiratory tract comes into 
contact with lung resident antigen presenting cells (APCs), consisting of macrophages and 
dendritic cells. These APCs will phagocytose the virus and process it into smaller protein 
segments called antigens. Viral antigens are then displayed, bound to MHC class I & II 
molecules on the outer membrane of APCs, to adaptive immune cells, such as B-cells and T 
cells. However, for APCs to reach most of the adaptive immune cells, they must migrate to 
secondary lymphoid tissues, such as lymph nodes or the spleen. Once there, APCs carrying viral 
antigens induce antibody production (humoral immunity), as well as cytotoxic T cell (CTL) and 
T helper (Th) cell responses (cellular immunity), initiating the primary adaptive immune 
response.12 
Once stimulated adaptive immune cells proliferate. B-cells differentiate into antibody 
secreting plasma cells and T cells differentiate to have various effector functions (Figure 2). 
Helper T cells play a critical role in the adaptive immune response to influenza, helping activated 
B-cells to produce and secrete antibodies and secreting cytokines that prime macrophages to 
destroy ingested microbes and cytotoxic T cells to kill infected target cells. Both humoral and 
cellular immunity are important for recovery from acute infection and resistance to reinfection. 
After infection has cleared many of the antigen-specific adaptive immune cells lose effector 
function and undergo apoptosis. A small pool of memory B-cell and T cells remain in body, 





Figure 1. The humoral and cellular immune response following infection with virus. From 
Influenza Report, 2006.  
In 2011, a study was published concerning the 2009 H1N1 influenza pandemic which 
established obesity, for the first time, as an independent risk factor for morbidity and mortality 
from infection with influenza virus.1 The researchers analyzed public health surveillance data to 
assess the association between obesity and death or illness from H1N1 influenza infection in 
patients 20 years or older. Out of the 534 adults that were assessed in this study 274 (51%) were 




prevalence of obesity in the state of California which was 23% at that time, and was 1.5 times 
greater than the prevalence of obesity in the United States (33%). Out of the 534 subjects that 
were analyzed in this study 92 (17%) died, 56 (61%) of which were obese and 28 (30%) of 
which were extremely obese (BMI>40kg/m2). Using multivariate analysis to control for other 
risk factors, such as asthma, age and immunosuppressive conditions, the researchers found that 
extreme obesity (BMI ≥ 40kg/m2) was associated with death, having an odds ratio of 2.8 with a 
95% confidence interval of 1.4-5.8.1  
Protection from the flu and other viruses is of great public health importance. Influenza is 
a highly contagious respiratory tract infection. In 1918-19, a deadly pandemic strain of the 
influenza virus, known as the Spanish Flu, resulted in approximately 21 million deaths 
worldwide.13 The recent 2009 influenza pandemic was responsible for 151,700 to 575,400 deaths 
worldwide.13  Pandemic flu refers to the introduction of a novel viral strain through antigenic 
shift due to the combination of multiple influenza viruses. When the resulting strain is 
dramatically different from the preceding strain, large proportions of the population will not have 
previously developed immunity against it.13 These strains are often introduced via zoonotic 
transfer from animals, such as pigs and birds. This genetic shift dramatically increases the risk of 
morbidity and mortality from influenza infection.  
Besides pandemic strains of influenza, seasonal influenza remains a serious public health 
threat due to constant changes in protein structure through antigenic drift each year.  Seasonal 
influenza affects all populations because of its relative ease of transmission via droplets from 
infected persons coughing, sneezing or talking. Typically, in the United States, influenza 
circulation occurs most prominently from October to May every year. The virus has been known 




specific chronic medical conditions such as immunodeficiency diseases, asthma and chronic 
heart or lung diseases and more recently obesity.1 The flu vaccine is still the single most 
effective method for protecting against the pathogen. 
Obesity and influenza vaccination 
Influenza vaccines commonly contain three or four inactivated forms of influenza A and 
B strains, making the vaccine either trivalent or quadrivalent. The influenza vaccination involves 
an intramuscular injection that changes from year to year in anticipation of circulating viral 
strains.14 The WHO, based on its continuous surveillance, identifies antigenic variants of the 
influenza virus and analyzes them for inclusion into the yearly vaccine. The selected strains of 
the virus are then grown in embryonated chicken eggs, extracted from the eggs’ allantonic fluid, 
inactivated, split, and combined to form the final administered vaccine. Once administered, the 
vaccine stimulates immunological memory development, without the threat of serious 
symptoms; thereby priming the immune system for a rapid, specific immune response, should 
exposure to influenza occur.  
Vaccination induced immunological memory responses produces a similar immune 
memory response as previously described following primary infection with influenza. Following 
vaccination, if re-exposure to the virus, vaccine induced-memory B-cells and T cells elicit a 
secondary response. Secondary immune responses happen more quickly (within 3-4 days) and 
are more effective than the primary response. B cells rapidly produce larger amounts of antibody, 
specific to the virus, called immunoglobulins (primarily IgG), and CD4+ and CD8+ T cells 
respond by secreting pro-inflammatory cytokines and by targeting and killing infected cells.  
In 2007, Smith et al. found that, following infection with influenza virus, diet-induced 




Obesity was found to inhibit the ability of the immune system to appropriately respond to 
influenza infection by reducing expression of antiviral cytokines and reducing natural killer (NK) 
cell cytotoxicity.15 NK cells are important innate immune cells that target and kill infected cells 
by inducing apoptosis. In 2012, Sheridan et al. found that obese adults successfully produced an 
antibody response to the influenza vaccine 30 days following vaccination.16 These findings 
suggest that the B-cells of obese individuals respond properly to the influenza vaccine. In a later 
study published in 2014 by Sheridan et al., this finding was confirmed.17 However, one year post 
vaccination, obese individuals were found to have a significantly lower antibody response 
compared to lean vaccinated individuals.16 
In 2017, a study by Neidich et al. demonstrates that flu-vaccinated obese adults were less 
protected from influenza.18 Despite vaccination and an antibody response that was not 
statistically different from the antibody response of lean adults, vaccinated obese individuals had 
twice the risk of influenza or influenza-like-illness.18 The antibody response to influenza is 
characterized using two terms, seroconversion and seroprotection. Seroconversion refers to a 4-
fold increase in antibody concentration in the serum (titer) and is associated with a 49% 
reduction in risk of influenza infection. Seroprotection refers to the subject having an antibody 
titer that is 40 hemagglutination inhibition (HAI) units or higher. Neither seroconversion nor 
seroprotection rates were statistically different between healthy weight and obese adults, 
suggesting the mechanism for increased risk of influenza and influenza-like-illness in obese 
subjects may be due to poor T cell function.  
T cells are known to play an important role in the adaptive immune response against 
influenza. CD4+ T helper cells are especially important in limiting disease severity by helping to 




assist with viral clearance.19 In a mouse model, diet-induced obesity was found to impair T cell 
memory response to the influenza virus.20 In this study 25% of diet-induced obese mice 
experienced mortality from an influenza infection, while none of their lean counter parts died 
from the infection. Obese mice were also found to have one third the number of influenza-
specific CD8+ T cells producing IFN-γ and mRNA expression for IFN-γ was 60% less in the 
lungs of obese mice as compared to lean infected mice.20 Further studies into the effects of 
obesity on influenza immunity found that CD4+ and CD8+ T cells of vaccinated obese 
individuals were defective. T cells of obese individuals expressed lower levels of activation 
markers (CD28 and CD69) and lower levels of functional markers (IFN-γ and GranB), as 
compared to lean individuals, in response to ex vivo challenge with live H1N1 virus.21 This 
poses an important question that has yet to be answered in full, why do T cells not function 
properly in obese individuals? 
T cell metabolism and obesity 
In a study done to characterize the role of T cells in obesity related inflammation, visceral 
fat from diet induced obese mice was found to contain a higher frequency of CD8+ IFN-γ and 
Granzyme B secreting T cells than visceral fat from lean mice.22 Granzyme B is an enzyme 
secreted by CD8+ cytotoxic T lymphocytes that signals apoptotic cell death in target cells. 
Levels of granzyme B and IFN-γ are naturally elevated in activated effector T cells in response 
to infection. In the obesogenic state, similar T cell characteristics are observed in the absence of 
infection. Consistent with this finding, Yang et al. demonstrates that diet induced obese mice 
have a reduction in peripheral naive T cells with increased frequency of effector and memory 
cells when compared to their lean counterparts.7 In a healthy lean individual the frequency of 




cells.22 These finding show that in the inflamed adipose environment, T cells are phenotypically 
different, expressing some of the traits of activated effector T cells and disconcertingly becoming 
pro-inflammatory without the stimulus of infection. To understand how this occurs, T cell 
metabolism must be considered. 
T cell functional demands are matched with a corresponding metabolic program (Figure 
1). The two main metabolic processes used by the cell to generate energy (ATP) are glycolysis 
and oxidative phosphorylation. Glycolysis is the cytosolic breakdown of glucose into two 
molecules of pyruvate, generating ATP in the process. Pyruvate generated from glycolysis can 
continue to be metabolized in the cytosol into lactate using the enzyme LDH (lactate 
dehydrogenase). In the presence of oxygen, this process is called aerobic glycolysis. 
Alternatively, pyruvate can be oxidized in the TCA cycle (tricarboxylic acid cycle), generating 
NAD to be used in the electron transport to generate ATP. Oxidative phosphorylation is a 
metabolic process that involves the conversion of pyruvate, derived from glucose and amino 
acids (AAs), as well as fatty acids into acetyl-CoA. Acetyl-CoA is further degraded into carbon 
dioxide in the TCA cycle in the mitochondria. Degradation of acetyl-CoA yields free electrons 
which are carried to the electron transport chain on electron carriers, NADH and FADH2. The 
electron carriers transfer their electrons to the complexes in the electron transport chain, resulting 
in the movement of protons out of the mitochondrial matrix. The electrochemical potential 
created by the process fuels the production of ATP in the presence of oxygen.  
These metabolic processes are regulated mainly by two important pleiotropic metabolic 
regulators, mammalian target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK). 
These cellular nutrition sensors respond to conditions inside the cell and are influenced by the 




through a wide range of immunological and metabolic cues.23 TCR engagement along with 
costimulation with CD28 activates mTOR through the Akt pathway. Signaling from other 
molecules such as IL-6, TNF-α, the adipokine, leptin, activates mTOR as well.  Activation of 
mTOR leads to a pro-growth phenotype in the presence of high energy signals. It regulates the 
transcription of enzymes involved in glucose metabolism, increases protein translation and 
increases lipid synthesis24. It also increases GLUT1 expression on the surface of T cells, 
increases rates of aerobic glycolysis, and promotes T cell effector differentiation. Some studies 
have shown that treatment of T cells with rapamycin, an inhibitor of mTOR, prevents T-eff 
(CD4+ effector T cell) growth and proliferation, providing evidence that mTOR acts to regulate 
both the metabolism and functional fate of T cells.24 
Working against mTOR is the complex AMPK. Whereas mTOR promotes a more 
glycolytic and pro-growth phenotype in the presence of high energy metabolites, AMPK 
maximizes energy production by catabolic pathways.24 AMPK is activated by low energy signals 
in the cell. High levels of AMP (adenosine monophosphate) relative to ATP promotes the 
phosphorylation and activation of AMPK, leading to increased levels of fatty acid oxidation in T 
cells through promotion of CPT-1 and inhibition large molecule synthesis.  AMPK is also 
required for T-reg (CD4+ Regulatory T cell) function.25 
Systemic metabolism can also influence T cell function. Circulating leptin and 
adiponectin, which are adipokine (cytokines secreted by adipocytes), can greatly enhance or 
suppress T cell function. Leptin and its receptor have structural and functional similarities to the 
IL-6 family of cytokines, which are known pro-inflammatory cytokines.26 Leptin is also reported 
to increase IFN-γ and IL-2 production in activated T cells. In genetically leptin deficient (ob/ob) 




and T cell effector function.25 Of note, treatment of fasted mice with leptin restored T cell 
proliferation and inflammatory cytokine production, both in vivo to fasted animals and in vitro to 
T cells isolated from fasted mice.25 Leptin is also required to upregulate the glucose transporter 
Glut1, allowing metabolic reprograming of activated effector T cells and fueling T cell 
proliferation and cytokine production.27 These studies and others have confirmed that leptin is 
required for proper function of activated T cells and plays an important role in the metabolism of 
the T cell.  
Adiponectin works inversely of leptin on T cells. While the role of adiponectin on T cell 
metabolism is not clear, adiponectin is known to be strongly immunosuppressive.8 T cells store 
adiponectin receptors intracellularly and express adiponectin receptors on the cell surface 
following stimulation.25 Adiponectin signaling in T cells helps to control the immune response, 
leading to decreased cytokine production, decreased proliferation, and apoptosis post antigen 
stimulation.28 
 
Figure 2. T-cell metabolism regulates T-cell function. The resting or memory T cell harvest the 
majority of its energy using oxidative phosphorylation (left). Activated T cells (right) rely 
heavily on aerobic glycolysis for energy production. This metabolic reprogramming corresponds 





For resting naïve and memory T cells the main source of energy is oxidative 
phosphorylation. The T cell’s preference is to funnel glucose through the TCA cycle, oxidizing it 
and other fuel sources (amino acids and lipids) for more efficient energy production. Oxidative 
phosphorylation results in the production of large amounts of ATP, which are used to satisfy the 
high energetic cost of cellular maintenance. Naïve and memory T cells, in their resting state, can 
exist in secondary lymphoid organs or in circulation for long periods of time until they are 
activated and as they are not proliferative, they have a low demand for biosynthetic molecules.29 
To maintain a steady state of energy production and self-maintenance, resting T cells rely on a 
balance between cell survival cytokines such as IL-4, IL-7 and IL-15 and other hormonal signals, 
like adiponectin.30 These signals can either be autocrine, paracrine, or endocrine. IL-4 is an 
autocrine signal that is produced and used by T cells to promote cell survival and size 
maintenance.30 IL-7 constantly circulates in the serum and is produced by stromal cells in the 
bone marrow as well as epithelial cells. Upon ligation with its receptor on T cells, IL-7 promotes 
homeostasis and survival through activation of the PI3K/Akt/mTOR pathway30 as well as 
supporting catabolic metabolism, by promoting mitochondrial biogenesis and fatty acid 
oxidation.31 The reliance on these external signals for energy is so great that even if naïve T cells 
are cultured with high levels of extracellular nutrients, in the absence of IL-4 or IL-7, they will 
die.29 Adiponectin also plays an important anti-inflammatory role in the regulation of T cells. In 
lean states adipocytes produce high amounts of adiponectin and in obese states circulating 
adiponectin levels are low.10  
Upon activation, the T cells undergo a metabolic transformation, switching, primarily, to 




ligation of their T cell receptor (TCR) and subsequent ligation of their costimulatory CD28 
molecules. Antigen presenting cells (APCs) expressing MHC molecules on their surface interact 
with the TCR. When MHC molecules on APCs are carrying antigenic proteins that the TCR can 
bind to, the TCR becomes engaged and initiates the activation signal. Then, costimulatory 
molecules on T cells, such as CD28, bind to their ligand on the APC, completing the signal. 
Following activation, functionality of the T cell shifts from self-maintenance to effector function, 
cytokine production and proliferation.24 Because of these new functional demands, T cells need 
to produce biosynthetic precursors for cell growth and proliferation. T cells start to utilize amino 
acids for protein synthesis and fatty acids for membrane synthesis rather than for energy 
production. To keep up with these demands, the metabolic program of the T cell shifts from a 
primarily oxidative state to a more glycolytic state, where aerobic glycolysis is now a major 
source of ATP production. 
T cells exploit three main signaling pathways, including PKC, AP-1, and NFkB to 
transduce the stimulatory signal, resulting in activation of the cell’s effector functions  and 
production of pro-inflammatory cytokines, like IFN-γ.32 These important signaling pathways 
converge on both metabolic and inflammatory pathways and influence functional outcomes.32 
The costimulatory molecule CD28 has a particularly strong convergence with growth factor 
signaling in T cells. CD28 ligation enhances the PI3k/Akt/mTOR pathway, which is also a direct 
target of insulin signaling.31 Activating mTOR promotes a pro-growth phenotype in T cells, 
enhancing cell survival, growth, and proliferation, which is necessary for activated T cells to 
protect against infection. After activation the clonal population of effector T cells increases 
dramatically and T cells rapidly induce glycolysis.29 The glycolytic pathway is fed by up-




glucose into the T cell, along with antigen stimulation, signals the induction of glycolytic 
enzymes such as lactate dehydrogenase (LDHA), hexokinase (HK) and phosphofructokinase 
(PFKFB3).25,33  
Through these processes, it has been shown that changes in systemic and cellular 
metabolism are immediately linked to T cell activation and function.24 The presence of increased 
circulating nutrients and leptin in the obesogenic state may be promoting the activation of mTOR 
in resting T cells, similar to the aberrant activation of T cells around inflamed adipocytes.34 
Activation of mTOR shifts the cells to become more glycolytic, similar to the metabolic program 
of an activated T cell. We have preliminary evidence suggesting that T cells from obese 
individuals are more glycolytic than those of lean individuals. The presence of excess nutrients 
in the blood and in the adipose tissue of obese individuals, along with the pro-growth and pro-
inflammatory molecules, results in the aberrant activation of immune cells.34 This means that T 
cells that would naturally be resting under normal conditions are instead in a pro-inflammatory 
state, even without being activated by antigen stimulation. Altering T cell metabolism to 
maintain a constant pro-growth phenotype could be responsible for immunological dysfunction 
in response to viral infection. There is sufficient evidence that the metabolic dysfunction 
associated with obesity is the cause of a reduced T cell response in obese individuals. However, 
the question still remains: how can the T cell response against influenza virus be improved in 
obese individuals?  
Metformin 
Metformin is an important drug treatment for T2D and has been for decades. It is 
recommended by the ADA (American Diabetic Association) as the first line of defense for newly 




patients by decreasing hepatic glucose production and increasing peripheral glucose uptake. 
Metformin acts by activating AMPK in a range of different cell types in the body including - 
hepatocytes, skeletal muscle cells, endothelial cells, pancreatic beta cells, peripheral blood 
mononuclear cells (PBMCs) and platelets.35 Mechanistically, metformin is known to inhibit 
complex I of the electron transport chain in the mitochondria, thereby increasing cytosolic levels 
of AMP and activating AMPK.35 As previously described, AMPK has a host of cellular 
metabolic effects, including inhibition of mTOR. 
Metformin has been considered for its cardio-protective effects and for its role in cancer 
treatments. More recently, the effects of metformin on immune cell metabolism and function 
have been studied. Macrophages have been found to be directly affected by metformin.36 In-vitro 
culture of macrophages from obese mice with metformin was found to increase levels of p-
AMPK and reduce production of inflammatory cytokines.36 Diaz et al. found that in-vivo and in-
vitro use of metformin was associated with increased levels of p-AMPK in B-cells and higher 
antibody titers.37 
Metformin has also been shown to act directly on T cells to activate AMPK in both CD4+ 
and CD8+ T cells.38,39 Administration of metformin in a murine asthma model was found to 
increase CD4+ T-reg numbers and decrease numbers of CD4+ T-effector cells. T-regs were found 
to have higher expression of p-AMPK.38 Lipid oxidation, as a result of AMPK activation, was 
upregulated in T-regs of metformin treated mice. T-effector cells are selectively inhibited by 
increased lipid oxidation while T-regs require lipid oxidation for function. These data suggest 
that activation of AMPK with metformin can change the fate of T cell populations through 




Metformin has also been shown to enhance CD8+ memory T cells in mice.39 Pearce et al. 
found that murine T cells cultured with metformin in the absence of IL-2 were found to have 
elevated levels of beta-oxidation.39 The study also demonstrates that in vivo metformin 
administration increased AMPK activation and enhanced CD8+ T cell memory formation in 
response to an experimental cancer vaccine. The mechanism by which this improved vaccine 
response occurred is not entirely clear, but the study suggests that regulation of fatty acid 
oxidation is partly responsible for the improvement in memory T cell formation. Consistent with 
this finding, inhibiting mTOR, an inhibitory target of AMPK,  during the memory formation 
phase improved the functional qualities of memory T cells.40 These data are important because 
the goal of vaccines is to generate CD8+ memory T cells that can quickly respond to infection.  
It is important to note that Zarrouk et al. found that metformin plays a role in the 
metabolic reprogramming of activated T cells but can do so in an AMPK independent manor.41 
This is not the first report of metformin acting to inhibit mTOR independent of AMPK 
signaling.42 Zarrouk et al. reported that metformin treated T cells had increased levels of AMPK 
but suggests that metformin can act on the T cell independent of AMPK. Isolated T cells from T 
cell specific deletion of AMPK knockout mice (AMPKα1null) and wild-type mice were treated 
with metformin. T cells from knockout mice and wild-type mice were both found to exhibit 
lower levels of mTOR activity, suggesting that metformin’s action on mTOR can be independent 
of AMPK activation. Metformin-treated, antigen receptor-activated T cells also showed reduced 
glucose uptake compared to control antigen-activated cells.41 
Given how T cell metabolism drives T cell function, metformin, through its activation of 




function. My hypothesize is that metformin will improve the memory T cell response and 







CHAPTER II – JOURNAL MANUSCRIPT1 
 
Overview 
Obesity has reached epidemic proportions in the United States over the past few decades 
and now affects more than one-third of the adult population. In recent years, obesity has been 
linked to increased risk of morbidity and mortality from influenza infection. The influenza 
vaccine is the most effective way to prevent infection with the influenza virus, however, despite 
vaccination, obese individuals have twice the risk of influenza or influenza-like-illness. Obesity 
has been shown to impair T cell activation and function. What is not known is how obesity 
causes the dysfunction. Recent studies have demonstrated that T cell function is heavily reliant 
on cellular metabolism and T cells will switch their metabolic profile in response to extracellular 
stimuli. Inflamed visceral adiposity, caused by inflammatory cells infiltrating hypertrophic 
adipose tissue, is a major hallmark of obesity. Visceral adipocytes of obese individuals release 
high levels of leptin and other pro-inflammatory cytokines into the serum. These changes in the 
extracellular environment of T cells may influence their metabolic profile and in turn, impair 
their function. Therefore, we hypothesized that the metabolic drug metformin would improve T 
cell function. We show that, compared to obese adults, influenza-vaccinated obese adults 
prescribed metformin have improved CD8+ memory T cell responses to in vitro challenge with 
influenza virus. T cells of obese metformin-treated adults express higher levels of activation and 
functional markers. These results suggest that metformin may help to restore memory T cell 
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function and act as an immunoenhancing agent for obese individuals at the time of vaccination. 
Further investigation into the metabolic effects of metformin on T cells is needed to uncover the 
mechanism(s) for metformin-driven improvements in memory T cell function. 
 
Introduction 
Obesity is now of epidemic proportions in the United States, reaching a prevalence of 
greater than 36.5% in adults and greater than 17% in children. The causes of obesity are 
numerous and complex and its consequences are likewise. Most commonly associated with 
having a BMI greater than 30kg/m2 is increased visceral adiposity that can manifest 
metabolically and cause low grade chronic inflammation.4 Obesity is associated with many 
chronic conditions such as type II diabetes (T2D), cardiovascular disease and metabolic 
syndrome.5 Obesity has also been associated with increased risk of postoperative infection, acute 
respiratory infection, and influenza infection.1,8,9 
In 2011, a study was published concerning the 2009 H1N1 influenza pandemic which 
established obesity, for the first time, as an independent risk factor for increased morbidity and 
mortality from infection with influenza virus.1 This finding was of great public health concern, 
because over two thirds of the U.S. population is overweight or obese, because seasonal 
influenza remains a public health threat.43 The influenza vaccine is the single most effective 
method for protecting against infection with the pathogen. The vaccine stimulates immunological 
memory development, priming the immune system for a rapid, specific immune response, should 
exposure to influenza occur. 
However, in 2012, Sheridan et al. found that obese adults successfully produced an 




suggest that the B-cells of obese individuals respond properly to the influenza vaccine, 
effectively producing antibodies against the influenza virus. However, at one year post 
vaccination, obese adults had a steeper decline in antibody response compared to lean adults.16 In 
2017, a study by Neidich et al. demonstrated that despite vaccination, obese individuals had 
twice the risk of influenza or influenza-like-illness.18 The influenza-specific antibody response of 
obese adults was not statistically different from the response of lean adults, suggesting the 
mechanism for increased risk of influenza and influenza-like-illness in obese subjects may be, 
instead, due to poor T cell function.18 
Further studies into the effects of obesity on influenza confirmed that T cells of obese 
mice and humans are impaired.19–21 Of note, CD4+ and CD8+ T cells of obese individuals 
expressed lower levels of activation markers (CD28 and CD69) and lower levels of functional 
markers (IFN-γ and GranB), as compared to lean individuals, in response to ex vivo challenge 
with live H1N1 virus.21 These findings and others lead to further investigation of T cell 
activation and function.  
T cell immunological demands are matched with a corresponding metabolic program.31 
These metabolic processes are regulated mainly by two important pleiotropic metabolic 
regulators, mammalian target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK). 
For resting naïve and memory T cells the main source of energy production is oxidative 
phosphorylation. However, upon activation, the T cell undergoes a metabolic transformation, 
switching, primarily, to aerobic glycolysis for energy production.31  
Well understood was the classical T cell activation through TCR engagement and 
costimulation with CD28 but more recently we have started to understand that T cells respond to 




directly associated with T cell inflammatory status.8,25,28 Obesity is associated with high levels of 
leptin, free fatty acids, IL-6, and TNF-α which are known modulators of pro-inflammatory 
pathways in T cells.25 These signals overlap on metabolic pathways as well, influencing the 
activation, differentiation and function of T cells.32 The target for these pro-inflammatory signals 
is mTOR activation, which leads to increased anabolic metabolism, namely glycolytic pathways. 
AMPK is a known inhibitor of mTOR and upregulates oxidation in T cells.31 Metformin 
is a metabolic drug that is most widely prescribed for type II diabetics, to help reduce blood 
glucose levels through activation of AMPK. Metformin has been studied in multiple immune 
cells, including B-cells, T cells and macrophages and has been shown to have anti-inflammatory 
effects.36,37 Metformin acts directly on T cells to activate AMPK and inhibit mTOR.39,41 
Metformin has also been shown to enhance CD8+ memory T cell formation in mice post 
vaccination and improve B-cell function in obese individuals.39 
These recent findings suggest that metformin could have a therapeutic role in protecting 
against influenza infection through modulation of T cell metabolism. This study examines the 
effects of metformin on T cell activation and function, as well as antibody levels, in vaccinated 
obese individuals. We hypothesized that metformin will improve the memory T cell 
response and antibody response to the influenza virus in obese vaccinated individuals. 
Methods & Materials 
Study Design & Subjects 
Study participants were chosen from a large clinical research study carried out at the 
University of North Carolina at Chapel Hill Family Medicine Center. All subjects were adult 
patients (≥18 years of age) who received the annual trivalent inactivated influenza vaccine (TIV). 




immunosuppressive drugs, acute febrile illness, history of hypersensitivity of any influenza 
vaccine components, history of Guillian-Barre syndrome, or use of theophylline preparations or 
warfarin.21 All procedures were approved by the Biomedical Institutional Review Board at the 
University of North Carolina at Chapel Hill. 
At enrollment, informed consent, demographic characteristics, height, weight, and a 
blood sample were obtained from each participant. Additional relevant information was 
obtained, with consent, from participants’ online medical records. A single dose of the TIV was 
given to each participant via intramuscular injection and a blood draw was obtained during the 
day of vaccination and again 30 days post vaccination. Blood was processed into serum and 
PBMCs as previously described.16  
A total of 3,304 participants were enrolled between 2009-2017. A group of 77 
participants, comprised of 40 obese non-diabetic (OB) subjects and 37 obese metformin-treated 
diabetic (OB+MET) subjects, were drawn from the last 3 years of the larger study (2014-2017). 
All samples are under the age of 60 years. Race was dichotomized into African American or 
Caucasian. PBMCs and serum samples obtained 30 days post vaccination were analyzed in this 
study. Demographics of each subject are included in Table 1 and Table 2.  
 
Cell Isolations & Stimulation.  
Frozen PBMC samples were taken from the -80°C liquid nitrogen tanks and thawed in a 
37°C water bath. Cells were washed, then plated in a 96 well flat bottom tissue-culture treated 
plate. Cells were cultured for 66 hours under three conditions, unstimulated, stimulated with 
20µL of stock H1N1 virus in media, or with 1µg of ConA in media at 37°C in 5% CO2. Cells 




PBMC Staining and Flow Cytometry  
PBMCs were stained with five fluorochrome-conjugated human antibodies: anti-CD3 
(FTIC), anti-CD4 (V450), anti-CD8a (APC), anti-CD69 (BV786), and anti-GranzymeB (PE). 
PBMCs were also stained with a viability dye, Zombie-Yellow (Biolegend). Extracellular 
staining was done using a FACS buffer (2% FBS). Permeablization was done using 
CtyoFix/CytoPerm (BD Bioscience) and intracellular staining was done using PermWash (BD 
Bioscience) buffer. Sample data was acquired using the AttuneNxT flow cytometer and were 
analyzed using FlowJo v10. The gating strategy is provided in Figure 3. 
Influenza Specific Antibody Determination 
The HAI titers were determined for all subjects using the WHOs (World Health 
Organization) guidelines and procedures.44 The HAI assay is an extremely reliable test and is the 
WHO test of choice for influenza surveillance.  
Identification of Intracellular Protein: Western Blot  
Intracellular protein levels of p-S6 S235/236, p-AMPK T172, and AMPK were 
determined using western blot assay. Whole PBMC pellets were lysed on ice for 20 min in RIPA 
buffer (150mM NaCl, 50mM Tris pH 7.4, 0.5% Na deoxycholate, 0.1% SDS, 0.1%NP40) 
containing SPP, BGP, Na3VO4(phosphatase inhibitors), and Halt (protease inhibitor cocktail). 
Protein content was determined by Bradford assay. Protein (30ug) was suspended in 
Laemmli buffer, and boiled for 5 minutes then run out on a 4-16% gradient SDS-PAGE gel. 
Followed by transferr to nitrocellulose membrane in Towbin buffer (25mM Tris, 192mM 
Glycine pH 8.3 20% methanol), with ponceau S solution for 1 min.  
Blots were washed 3 times or 5min in TBST (150mM NaCl, 50mM Tris pH7.2 .1%tween20), 




Blots were the incubated at 4C overnight in specific antibodies at 1:1000 dilution in 5% 
BSA/TBST. Blots were then washed 3 times for 5min TBST, followed by incubation with 
1:10000 dilution of goat anti rabbit/mouse (licor [P/N 925-32211], [P/N 925-68070]) 
5%BSA/TBST at room temp for 1 hour. Protein was detected using LI-COR Odyssey imaging 
system. All blots were run in technical quadruplicates and densitometry was determined using 
image studio lite software. 
Statistical Analysis.  
Data presented were analyzed using Two-way ANOVA with Sidak's multiple 
comparisons test and parametric unpaired T-tests on Graphpad Prism v7.  
 
Results 
OB and OB+MET Group show no significant differences in the number of CD4+ or 
CD8+ T cells. The number of CD4+ and CD8+ T cells in both groups were not significantly  
different in unstimulated cultures and remained the same upon stimulation. Data not shown.  
 
CD4+ T cells from OB and OB+MET subjects show no significant differences in 
expression of activation marker CD69. CD69 expression is indicative of activation status, where 
T cells that are activated will express higher levels of CD69. CD4+ T cells from the OB and 
OB+MET group did not express significantly different levels of CD69. However, a trend was 
observed in the difference between the OB and OB+MET group in the number (p=0.0975) and 
percent (p=0.0728) of CD4+ T cells expressing CD69. Individual subjects in the OB+MET 




When comparing the median fluorescence intensity (MFI) (Figure 4), there is no significant 
difference between the OB and the OB+MET group (p=0.8523).  
 
CD4+ T cells of OB subjects have a significantly greater fold change in expression of 
CD69. The fold change was calculated by dividing the percent of CD4+CD69+ T cell in the 
unstimulated cultures by the percent of CD4+CD69+ T cells in the influenza stimulated culture 
for each group. The fold change of the percent of CD4+CD69+ T cells from unstimulated to 
influenza stimulated in the OB group is significantly greater than the fold change seen in the 
OB+MET group (p=0.0204) as well as with the fold change in numbers (p=0.0256) (Figure 5).  
 
The number and frequency of CD8+GranB+ T cells is not influenced by metformin 
treatment. Granzyme B is an enzyme produced by T cells that signals programmed cell death in 
infected cells. The number of CD8+GranB+ T cells in the OB+MET group was not significantly 
increased compared to the OB group in both the unstimulated (p=0.1077) and influenza 
stimulated (p=0.0503) condition. Although OB+MET subjects had a higher percent of CD8+ T 
cells that expressed GranzymeB in both the unstimulated (p=0.3874) and influenza stimulated 
(p=0.3353) conditions, this finding is not significant (Figure 6).  
 
CD8+ Memory T cells from obese metformin-treated diabetic adults express a higher 
frequency of CD69+GranB+ T cells than obese non-diabetic adults. In response to exposure 
with live H1N1 A/California/7/2009 virus, obese metformin-treated diabetic adults had 
significantly higher percentages of CD8+ T cells expressing both the activation marker (CD69) 




significantly different as compared to the OB group (p=0.2421). The unstimulated cultures 
showed no difference in the percent of CD8+CD69+ or CD8+CD69+GranB+ T cells (Figure 7).  
 
Influenza specific antibody concentrations post-vaccination trend higher in the 
metformin treated individuals compared to obese non-diabetics. The A/California/7/2009 H1N1 
antibody titers increased in both groups post vaccination, regardless of metformin treatment 
status.  No differences were seen in rates of seroconversion, defined as a four-fold or greater 
increase in antibody titer following vaccination. Although, post vaccination, OB+MET subjects 
had a trend towards an increase in mean antibody titer compared to that of OB subjects, this 
finding was not significant (p=0.0776) (Figure 8).  
 
Preliminary data to suggest higher levels of phosphorylated AMPK and phosphorylated 
downstream activation marker of mTOR expressed in PBMCs of OB+MET subjects. Western 
blot analysis was done on whole PBMCs from 4 OB and 6 OB+MET subjects (Figure 9) (Table 
4). Because of high levels of protein degradation in some samples, data from only 2 OB and 2 
OB+MET subjects are presenedt. Expression of pAMPK was found to be higher in the two 
OB+MET subjects as compared to the two OB subjects. Expression of p-S6, a downstream 
activation marker of mTOR, was also found to be higher in the OB+MET group as compared to 
the OB group.  
 
Discussion 
Previous studies in our lab suggest that the adaptive immune response of obese mice and 




seen across all immune cells however. Obese individuals were found to have a successful 
antibody response 30 days post vaccination, suggesting that B-cells are responding appropriately 
to the influenza vaccination. However, despite vaccination, obese individuals are two times as 
likely to have influenza or influenza like illness. Further studies pointed to T cells in obese 
individuals being the source of impaired immune response. T cells from obese individuals were 
found to express lower levels of activation markers CD69 and CD28 and lower levels of 
functional markers IFN-γ and Granzyme B. Impairments in T cell function were also found in 
diet-induced obesity studies in mice.  
Recently, T cell metabolism has been found to have a direct relationship with T cell 
activation, differentiation and function. In a resting state, T cells are highly oxidative, using 
OXPHOS as the primary source for energy metabolism. Upon antigen stimulated activation, T 
cells undergo a metabolic shift and become highly glycolytic. Activated T cells use mainly 
aerobic glycolysis for energy metabolism (Figure 2). We have preliminary data to suggest that T 
cells of obese individuals are more glycolytic, having a higher utilization of glucose per unit time 
and having higher expression of glycolytic markers such as hexokinase-2 and Glut-1. These data 
and the current body of research suggest that if the metabolism of the T cell is impaired, then so 
too is its function. Therefore, restoring metabolism may restore T cell function and improve the 
adaptive immune response to influenza vaccination.  
Metformin, a metabolic drug used to treat patients with type-II diabetes, has been found 
to affect T cell metabolism directly by activating AMPK and inhibiting mTOR. Activation of 
AMPK and inhibition of mTOR through administration of metformin could be a key target for 




treated diabetic (OB+MET) subjects have improved CD8+ memory T cell responses compared 
to obese non-diabetic (OB) subjects not taking metformin.  
In response to stimulation with A/California/7/2009 influenza virus, OB+MET subjects 
exhibited significantly higher levels (p = 0.0433) of CD8+ T cells expressing both CD69 and 
granzyme B (CD8+CD69+GranB+). This finding reinforces that administration of metformin at 
time of vaccination enhances memory T cell generation and results in greater protective 
immunity.39 Furthermore, CD8+ T cells of OB+MET subjects expressed higher overall levels of 
granzyme B than did OB subjects. While there were no significant differences in the overall 
independent expression of CD69 and granzyme B in influenza stimulated CD8+ T cells, trends 
were observed in the OB+MET group. Influenza stimulated CD8+ T cells of OB+MET subjects 
expressed non-significant increases in CD69 expression (p=0.2421) and granzyme B expression 
(p=0.0503). When considering the effects of metformin use on CD4+ T cells, no significant 
differences were seen in expression of CD69. However, interestingly, a trend, similar to CD8+ T 
cell, CD4+ T cells from OB+MET subjects display non-significantly higher percentages (p = 
0.0728) and numbers (p=0.0975) of CD69 expression.  
Further analysis uncovered a significant difference in the fold change of CD4+CD69+ T 
cells between the unstimulated and influenza stimulated conditions between OB and OB+MET 
groups. OB subjects had a significantly higher fold change in the number (p = 0.0256) and 
percent (p = 0.0204) of CD4+CD69+ T cells. Small changes in the denominator could have large 
effects on the fold change. Therefore, these findings, are likely observed because higher levels of 





CD4+ T cells are made up of a diverse set of cell subtypes that have specialized 
metabolism and function including Th1, Th2, Th17, Tfh and T-reg subsets. Metformin treatment 
could be influencing the activation and/or function of any one of these subtypes. T-regs are of 
particular relevance because they are regulated primarily by AMPK.24 Stimulation of AMPK in 
vivo with the AMPK activator metformin has been found to increase T-reg numbers.24  
 Influenza specific antibody concentrations HAI titers were also assessed. No significant 
differences between the OB group and the OB+MET group were observed. However, the 
OB+MET group did have a non-significant increase in the mean antibody titer as compared to 
the OB group (p = 0.0776). Interestingly this is in contrast with to Diaz et al. 2017, in which 
metformin use was found to increase antibody titer. However, the researchers report the dosage 
patients were taking (1000 mgs of MET twice/day), the duration of treatment ( ≥ 3 years), and 
they report that none of their MET treated participants had any side effects or had to stop MET 
treatment before completion of the study.37 
Interestingly, the highest expression of CD69 and GranB, as well as the highest antibody 
concentrations are always observed in the metformin treated group. This trend suggests that 
metformin may be having an effect on immunity but that these effects are dampened by the large 
variation seen in the antibody concentration and CD4+ and CD8+ T cell response of OB+MET 
subjects. For most of the results, the only information we have on OB+MET subjects regarding 
their metformin status is that they have been prescribed metformin after being diagnosed with 
T2D. This does not confirm whether or not subjects are taking metformin as prescribed. Further, 
no information about length of treatment nor the dosage of the prescription was available. Lastly, 
it is also entirely possible that genetic differences exist with regard to T cell responsiveness 




Further assays were conducted to discover the effects of metformin on the protein 
expression of two important cellular metabolic regulators, AMPK and mTOR. As expected, the 
subjects in the OB+MET group expressed higher levels of phosphorylated AMPK, the activated 
form of the protein, than subjects in the OB group. However, unexpectedly, subjects in the 
OB+MET group also expressed higher levels of p-S6, a downstream marker for mTOR 
activation. Because of small sample size (n=4), there is not enough information to make any 
conclusions, however, it is an interesting finding that requires further examination.  
This study offers the first reports of metformin-induced activational and functional 
differences in human memory T cells. While much of the data shown here does not meet 
significance level (p < 0.05), the trends suggest important differences between the activation and 
function of CD4+ and CD8+ T cells of OB and OB+MET individuals. Further investigation into 
the metabolic effects of metformin on T cells is needed to uncover the mechanism(s) for 












Sex  Age  Race BMI Diabetes Metformin  Assays  
Flow  HAI Western 




























✓ ✓   
2 Female 31.6 African American 33.1 ✓ ✓   
3 Female 42.0 African American 42.9 ✓     
4 Female 43.7 African American 37.2 ✓ ✓   
5 Female 46.4 African American 59.5   ✓   
6 Female 50.6 African American 31.4 ✓ ✓   
7 Female 50.8 African American 41.4 ✓ ✓   
8 Female 51.1 African American 34.6 ✓ ✓   
9 Female 51.9 African American 40.4 ✓ ✓   
10 Female 52.8 African American 40.2   ✓   
11 Female 53.0 African American 37.2 ✓ ✓   
12 Female 54.0 African American 36.8   ✓   
13 Female 55.0 African American 37.7 ✓ ✓   
14 Female 55.0 African American 37.0 ✓ ✓   
15 Female 55.6 African American 34.6 ✓ ✓   
16 Female 56.1 African American 36.8 ✓ ✓   
17 Female 60.8 African American 30.4 ✓ ✓   
18 Female 61.7 African American 34.3   ✓   
19 Female 63.7 African American 39.1   ✓   
20 Female 38.4 Caucasian 49.3   ✓   
21 Female 44.9 Caucasian 30.3   ✓   
22 Female 51.3 Caucasian 43.8 ✓ ✓   
23 Female 52.0 Caucasian 37.1   ✓ ✓ 
24 Female 52.6 Caucasian 32.4 ✓ ✓   
25 Female 60.2 Caucasian 52.0 ✓ ✓   
26 Female 63.2 Caucasian 33.0   ✓   
27 Female 64.0 Caucasian 50.8   ✓   
28 Male 45.3 African American 42.2 ✓ ✓   
29 Male 46.2 African American 41.0 ✓ ✓   
30 Male 60.0 African American 31.3 ✓ ✓   
31 Male 61.0 African American 30.7 ✓ ✓   
32 Male 43.8 Caucasian 41.0 ✓ ✓   
33 Male 44.8 Caucasian 41.0   ✓   
34 Male 48.2 Caucasian 30.5 ✓ ✓   
35 Male 60.6 Caucasian 36.4   ✓ ✓ 
36 Male 64.1 Caucasian 39.1 ✓ ✓   




Table 2. Demographic information for obese non-diabetic (OB) group 
Subject 
# 
Sex  Age  Race BMI Diabetes Metformin 
Flow HAI Western 













  ✓   
2 Female 32.8 African American 35.4 No   ✓   
3 Female 27.1 African American 35.1 No ✓     
4 Female 41.8 African American 43.4 No ✓     
5 Female 43.0 African American 37.7 No   ✓   
6 Female 47.4 African American 61.1 Type 2 ✓ ✓   
7 Female 53.2 African American 31.0 No   ✓   
8 Female 57.8 African American 40.3 No   ✓   
9 Female 51.0 African American 34.0 No ✓ ✓   
10 Female 55.0 African American 40.8 No   ✓   
11 Female 53.2 African American 39.9 No   ✓   
12 Female 53.0 African American 34.7 No ✓ ✓   
13 Female 60.0 African American 37.4 No   ✓   
14 Female 58.8 African American 37.9 No   ✓   
15 Female 57.0 African American 36.6 No   ✓   
16 Female 56.6 African American 36.0 No ✓ ✓   
17 Female 57.9 African American 34.0 No   ✓   
18 Female 57.7 African American 31.0 No   ✓   
19 Female 61.8 African American 32.9 No ✓ ✓   
20 Female 63.2 African American 41.7 Type 2 ✓ ✓   
21 Female 33.6 Caucasian 48.3 No   ✓   
22 Female 48.1 Caucasian 30.7 No   ✓   
23 Female 49.5 Caucasian 41.0 No ✓ ✓   
24 Female 53.0 Caucasian 37.3 No   ✓   
25 Female 53.0 Caucasian 32.3 No   ✓   
26 Female 59.4 Caucasian 33.8 No ✓     
27 Female 66.0 Caucasian 53.0 No   ✓   
28 Female 63.5 Caucasian 32.0 No ✓ ✓   
29 Female 63.0 Caucasian 50.4 No   ✓   
30 Male 56.5 African American 41.8 No   ✓   
31 Male 53.5 African American 40.4 No   ✓   
32 Male 60.7 African American 34.2 No ✓ ✓   
33 Male 57.7 African American 32.7 No ✓ ✓   
34 Male 45.9 Caucasian 41.6 No ✓ ✓ ✓ 
35 Male 49.0 Caucasian 42.6 No ✓ ✓ ✓ 
36 Male 55.1 Caucasian 32.1 No ✓     
37 Male 49.8 Caucasian 30.8 No ✓ ✓   
38 Male 59.6 Caucasian 33.9 No ✓ ✓   
39 Male 64.7 Caucasian 39.3 No ✓ ✓   








Figure 3. Complete gating strategy for CD8+ T cells. Each subsequent chart represents the 
gated proportion of the one before it in the gating lineage. This gating tree ends with 
CD3+CD8a+CD69+GranB+ T cells in the upper right quadrant of the last chart.  
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Figure 4. Number, percent and MFI of CD4+CD69+ T cells for OB and OB+MET group. 
PBMCs from OB (n=22) and OB+MET (n=24) subjects were cultured in RPMI buffer, 
unstimulated and infected with live H1N1 virus. The percent (p=0.0728) and number 
(p=0.0975)of CD4+CD69+ T cells from OB+MET subjects trends higher than the CD4+CD69+ 
T cells of OB (A-B). No difference was seen between the MFI of CD4+CD69+ T cells of OB 
and OB+MET subjects (C). The unstimulated cultures showed no significant differences (A-C). 
Data points are individual subjects plotted with mean ± SD. Two-way Anova with Sidak's 
multiple comparisons test. 
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Figure 5. Fold change of number, percent and MFI of CD4+CD69+ T cells for OB and 
OB+MET group. Significant differences were observed in the fold change of the number and 
percentages of CD4+CD69+ in OB and OB+MET subjects. OB subjects expressed a 
significantly higher fold increase in both number (0.0256) and percent (0.0204) but not MFI 
(p=0.3214) of CD4+CD69+ T cells (A-C). The unstimulated cultures showed no significant 
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Figure 6. The number and percent of CD8+GranB+ T cell, OB and OB+MET subjects. No 
significant differences were observed in the number (p=0.0503) or percent (p=0.3353) of 
CD8+GranB+ T cells. The unstimulated cultures showed no significant differences. Data points 
are individual subjects plotted with mean ± SD. Two-way Anova with Sidak's multiple 
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Figure 7. The percent of CD8+CD69+ and CD8+CD69+GranB+ T cells, OB and OB+MET 
subjects. No significant differences were observed in the percent of CD8+CD69+ T cells 
(p=0.2421) in OB and OB+MET subjects. OB+MET subjects expressed significantly increased 
percentages of CD8+CD69+GranB+ T cells (p=0.0433). The unstimulated cultures showed no 
significant differences. Data points are individual subjects plotted with mean ± SD. Two-way 











































1 2 0 0






























U n s t im u la te d In f lu e n z a
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0















O B + M E T





1 2 0 0
1 6 0 0
0.0776










Figure 8. Influenza specific HAI antibody titers and fold change for A/California/7/2009, 
OB and OB+MET subjects. HAI titers increased from pre- to post-vaccination in both OB 
(n=36) and OB+MET (n=36) subjects. No significant differences were observed in the HAI 
titers between the OB and OB+MET (p=0.0776). Data points are individual subjects plotted 
with mean ± SD. Two-way Anova with Sidak's multiple comparisons test. There was no 
significant difference between OB and OB-MET subjects in the fold change of the antibody 
titers pre- and post-vaccination (0.4627). Data points are individual subjects plotted with mean ± 














Figure 9. AMPK, p-AMPK and p-S6 protein levels in PBMCs of OB and OB+MET 
subjects. Western blot analysis on PBMCs of OB (obese non-diabetic) (n=2) and OB+MET 
(obese metformin treated diabetic) (n=2) was done in quadruplicate on four individual gels. 
Tests revealed higher levels of p-AMPK and p-S6 in OB+MET group. Small sample size limits 
statistical power.    
 p s6/b actin      
 gel 1  gel 2  gel 3  gel 4  average 
ob 2 0.638469 0.847486 0.474473 0.41396 0.593597 
ob 3 1.361531 1.152514 1.525527 1.58604 1.406403 
m 1 11.06157 6.959167 11.86413 11.98413 10.46725 
m 4 5.336508 5.34244 6.36908 5.715333 5.69084 
      
      
p ampk/b actin      
 gel 1  gel 2  gel 3  gel 4  average 
ob 2 0.897279 0.738239 0.925168 0.62043 0.795279 
ob 3 1.102721 1.261761 1.074832 1.37957 1.204721 
m 1 1.693211 4.078643 2.228951 3.729606 2.932603 
m 4 1.879823 4.115368 1.875329 2.924678 2.6988 







CHAPTER III – SIGNIFICANCE & FUTURE DIRECTIONS 
The CDC estimates that during the 2016–2017 influenza season, the influenza virus 
infected 30.9 million people, resulted in 14.5 million visits to a health care provider, and 
hospitalized 600,000 people. These numbers make it clear that seasonal influenza still poses a 
great threat to the entire population. However, the burden falls disproportionately on those who 
are obese.1 Given the growing proportion of obese children and adults in the United States, it is 
critical that we understand how obesity-driven impairments in T cell immunity to influenza 
infection can be rectified.  
This work is the first to show differences in the activation and functional status of T cells 
in response to metformin treatment in humans. CD8+ T cells from vaccinated obese metformin-
treated diabetic patients showed improved memory response to in vitro stimulation with 
influenza virus. CD8+ T cells of obese metformin-treated diabetic (OB+MET) subjects 
expressed significantly increased levels of CD69+GranB+ cells. Similarly, although not 
significant, analogous trends were observed in the overall expression of CD69 and GranB in 
CD8+ T cells and in expression of CD69 in CD4+ T cells. OB+MET subject also had a non-
significant increase in their influenza specific antibody concentration compared to the obese non-
diabetic (OB) group. 
Interestingly, the fold change between unstimulated and influenza stimulated conditions 
was significantly increased in obese non-diabetic (OB) subjects. This is likely due to the 




varying metabolic profiles. Metformin, through regulation of CD4+ T cell metabolism, could be 
driving up the number of T-regs by activation of AMPK.24   
These findings suggest that metformin could have an enhancing effect on adaptive 
immunity against influenza infection. The mechanisms by which this happens is not clear. 
However, one proposed mechanism is that metformin could directly be impacting T cell 
metabolism by activating AMPK and inhibiting mTOR. T cell immunity is known to be driven 
by metabolism and metformin has been shown to alter T cell metabolism.41 Metformin has been 
shown to be effective in the treatment of cancer and has anti-inflammatory effects that may help 
alleviate some of the stresses associated with obesity-associated inflamed visceral adipose 
tissue.36 These findings, along with ours, suggests that metformin is a promising target for 
immunoenhancing therapies.  
The major strength of this study is that it provides the first look into the effects of 
metformin on T cell mediated immunity to influenza infection. We show that administration of 
metformin could enhance the CD8+ memory T cell response in vaccinated obese adults. Further, 
the two study groups are evenly matched having very similar mean age and BMI with an evenly 
distributed sex and race across the two study groups. Finally, the data is strengthened by a large 
and diverse sample size (n=77).  
This study also had several limitations. First, and most importantly, is the lack of detail 
about metformin use in metformin-treated subjects. There was no available information about 
duration of use, dosages, or whether or not participants were in-fact taking the drug. Little 
information was available on the participants’ blood glucose levels. Secondly, high variability 
within metformin-treated group could have been due to any of those factors that we do not have 




in the metformin-treated group, we were able to observe a significant difference in the percent of 
CD8+CD69+GranB+ T cells.  Finally, this study does not provide a clear link to how metformin 
may be affecting the metabolism of memory T cells. 
The results of this study and its limitations pose some interesting questions moving 
forward. First, does metformin have a different effect on different people or was the variability 
noted above a product of dosage or misuse? To answer this question, an HPLC-MS assay could 
be done to determine level of metformin and metformin metabolites in the serum of metformin-
treated subjects. This would confirm if participants who are prescribed metformin are in-fact 
taking their prescribed dose. Blood glucose and HbA1c levels could also be assessed more 
thoroughly to determine whether or not metformin is helping to control participants/ 
hyperglycemia.  
Second, to help illuminate the mechanism by which metformin is acting, a mitochondrial 
stress test could be done to determine oxygen consumption rates (OCR) and extracellular 
acidification rates (ECAR). This assay would provide critical information about the glycolytic 
and oxidation rates of T cells, which is a key characteristic of their functional status. Also, 
AMPK and mTOR are important regulators in T cell metabolism and function and are direct 
targets of metformin. Using a western blot assay to determine intracellular protein levels would 
help to reveal the mechanism by which metformin is acting.  
The effect of metformin on T cells, seen in this study, warrants further investigation into 
mechanism that drives memory T cell improvement. Together with future research, these 
findings may help to alleviate the burden of influenza on obese adults and help provide a tailored 
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